ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1467

Effectiveness of the Making It Work™ Program at Improving Presenteeism and Work Cessation in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial

Andre Luquini1, Yufei Zheng2, Hui Xie3, Catherine Backman1, Pamela Rogers3, Alex Kwok3, Astrid Knight3, Monique Gignac4, Dianne Mosher5, Linda Li1, John Esdaile6, Carter Thorne7 and Diane Lacaille1, 1University of British Columbia / Arthritis Research Canada, Richmond, BC, Canada, 2Simon Fraser University / Arthritis Research Canada, Richmond, BC, Canada, 3Arthritis Research Canada, Richmond, BC, Canada, 4Institute for Work & Health / University of Toronto, Toronto, ON, Canada, 5University of Calgary, Calgary, AB, Canada, 6Arthritis Research Canada, Vancouver, BC, Canada, 7Southlake Regional Health Centre, Newmarket, ON, Canada

Meeting: ACR Convergence 2020

Keywords: Disability, Employment, longitudinal studies, Randomized Trial, work

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Epidemiology & Public Health II: Risk Factors & Outcomes (1467–1471)

Session Type: Abstract Session

Session Time: 4:00PM-4:50PM

Background/Purpose: Arthritis often leads to presenteeism (decreased at-work productivity) and permanent work disability, the worst occupational outcome of a disease, leading to reduced quality of life and cost to society. Yet, health services addressing employment needs of people with arthritis are lacking. We evaluated the effectiveness of the Making-it-WorkTM (MIW), an online program developed to help people with inflammatory arthritis (IA) deal with employment issues.

Methods: A multi-center RCT evaluated the effectiveness of MIW at improving presenteeism and work cessation (WC) over two years. Participants were recruited from rheumatologist practices, consumer organizations and arthritis programs, in three provinces. Eligibility criteria: diagnosis of IA, employed, age 18-59, and concerned about ability to work. Participants were randomized 1:1 to MIW or usual care plus printed material on workplace tips. MIW consists of five online self-learning modules and group meetings, and individual vocational counselling and ergonomic assessments. Questionnaires were administered every 6 months. Outcomes were presenteeism [Rheumatoid Arthritis Work Instability Scale (RA-WIS)], time to WC of ≥6 months duration, and time to WC ≥2 months (secondary outcome). Baseline characteristics (age, gender, ethnicity, occupation, education, disease duration and self-employment) were collected. Intention-to-treat longitudinal analysis of RA-WIS using linear mixed effect regression models with 2-year comparison as primary endpoint and survival analysis for time to WC using Kaplan-Meier and Cox Proportional Hazard models were performed. Sensitivity analyses were conducted with missing values imputed using last observation carried forward and worse possible outcomes; with square root transformation of RA-WIS outcome; and adjusting for baseline covariates. SAS version 9.4 was used.

Results: A total of 564 participants were recruited, with 85% completing 2-year follow-up. Baseline characteristics were similar between groups. Difference in means of RA-WIS scores was significantly lower in the intervention group from 6 months onwards, with the greatest difference observed at 2 years (-1.78, 95%CI: -2.7, -0.9, p< .0001), yielding a standardized effect size of 0.32. Sensitivity analysis revealed satisfactory robustness of results. Work cessation occurred less often in intervention than control groups, but only reached statistical significance for WC duration ≥2 months ( WC ≥6 months: 31 vs 44 events, aHR 0.70, 95%CI: 0.44, 1.11, p-value: 0.13; WC ≥2 months: 39 vs 61 events, aHR: 0.65, 95%CI: 0.43, 0.98, p-value: 0.04).

Conclusion: Results of the RCT reveal the program was effective at improving presenteeism and preventing short-term WC. Effectiveness at preventing long-term work disability will be assessed at 5 years. This program fills one of the most important unmet needs for people with inflammatory arthritis.

Table 1. Sample characteristics

Figure 1. Effectiveness of the Making-it-Work(TM) program on Presenteeism and Work Cessation over 2 years


Disclosure: A. Luquini, None; Y. Zheng, None; H. Xie, None; C. Backman, None; P. Rogers, None; A. Kwok, None; A. Knight, None; M. Gignac, None; D. Mosher, None; L. Li, None; J. Esdaile, None; C. Thorne, Abbvie, 1, 2, Amgen, 1, 2, Celgene, 1, 2, CaREBiodam, 1, Centocor, 1, Janssen, 1, Lilly, 1, Medexus/Medac, 1, 2, Merck, 1, Novartis, 1, 2, Pfizer, 1, 2, Sanofi, 1; D. Lacaille, None.

To cite this abstract in AMA style:

Luquini A, Zheng Y, Xie H, Backman C, Rogers P, Kwok A, Knight A, Gignac M, Mosher D, Li L, Esdaile J, Thorne C, Lacaille D. Effectiveness of the Making It Work™ Program at Improving Presenteeism and Work Cessation in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/effectiveness-of-the-making-it-work-program-at-improving-presenteeism-and-work-cessation-in-workers-with-inflammatory-arthritis-results-of-a-randomized-controlled-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effectiveness-of-the-making-it-work-program-at-improving-presenteeism-and-work-cessation-in-workers-with-inflammatory-arthritis-results-of-a-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology